RxDoctor Payments Data

Meena Rijhwani, MD

Internal Medicine · Walnut Creek, CANPI 1316952799

Payments from drug & device makers

$1,610in general payments, 2019–2025

Across 79 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$240
  • Johnson & Johnson$229
  • Lilly USA, LLC$217
  • Impulse Dynamics (USA) Inc.$187
  • Pfizer$167
  • Boehringer Ingelheim$95
  • plus $475 from 16 others

What the payments were for

  • Food & beverage$1,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,610 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$72,903
Medicare patients
237
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$52,624
EliquisApixaban52$43,480
MyrbetriqMirabegron14$11,290
Wixela InhubFluticasone Propion/Salmeterol19$5,927
Atorvastatin Calcium412$3,649
Levothyroxine Sodium308$3,422
Rosuvastatin Calcium194$3,218
Gabapentin115$2,282
Albuterol Sulfate HfaAlbuterol Sulfate46$2,201
Baclofen25$1,630
Nebivolol Hcl14$1,507
Losartan Potassium129$1,413
Metoprolol Succinate76$1,409
Fluticasone Propionate82$1,375
Pantoprazole Sodium118$1,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$95$52,62438 claims
PfizerEliquis$167$43,48052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →